Literature DB >> 26622634

Number of cerebral lesions predicts freedom from new brain metastases after radiosurgery alone in lung cancer patients.

Dirk Rades1, Stefan Huttenlocher2, Mai Trong Khoa3, Pham VAN Thai4, Dagmar Hornung5, Steven E Schild6.   

Abstract

Numerous patients with few brain metastases receive radiosurgery, either alone or in combination with whole-brain irradiation. The addition of whole-brain irradiation to radiosurgery reduces the rate of intracerebral failures, particularly the development of new cerebral lesions distant from those treated with radiosurgery. Less intracerebral failures mean less neurocognitive deficits. However, whole-brain irradiation itself may lead to a decline in neurocognitive functions. Therefore, a number of physicians have reservations with regard to adding whole-brain irradiation to radiosurgery. Prognostic factors that allow an estimation of the risk of developing new cerebral metastases can facilitate the decision regarding additional whole-brain irradiation. Since primary tumors show a different biology and clinical course, prognostic factors should be identified separately for each primary tumor leading to brain metastasis. The present study investigated 10 characteristics in a series of 98 patients receiving radiosurgery alone for 1-2 cerebral metastases from lung cancer, the most common primary tumor associated with brain metastasis. These characteristics included radiosurgery dose, age, gender, performance status, histology, number of cerebral lesions, maximum total diameter of cerebral lesions, main location of cerebral lesions, extracranial spread and interval from first diagnosis of lung cancer to administration of radiosurgery. On univariate analysis, the number of cerebral lesions prior to radiosurgery (1 vs. 2 lesions) was the only characteristic significantly associated with freedom from new brain metastases (P=0.002). In cases of 2 lesions, 73% of patients developed new cerebral lesions within 1 year. On multivariate analysis, the number of brain metastases remained significant (risk ratio, 2.46; 95% confidence interval, 1.34-4.58; P=0.004). Given the high rates of new cerebral lesions in patients with 2 brain metastases, these patients should be strongly considered for additional whole-brain irradiation.

Entities:  

Keywords:  lung cancer; new brain metastases; number of cerebral lesions; radiosurgery; whole-brain irradiation

Year:  2015        PMID: 26622634      PMCID: PMC4509016          DOI: 10.3892/ol.2015.3370

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  12 in total

1.  Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.

Authors:  Hidefumi Aoyama; Hiroki Shirato; Masao Tago; Keiichi Nakagawa; Tatsuya Toyoda; Kazuo Hatano; Masahiro Kenjyo; Natsuo Oya; Saeko Hirota; Hiroki Shioura; Etsuo Kunieda; Taisuke Inomata; Kazushige Hayakawa; Norio Katoh; Gen Kobashi
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone.

Authors:  Hidefumi Aoyama; Masao Tago; Norio Kato; Tatsuya Toyoda; Masahiro Kenjyo; Saeko Hirota; Hiroki Shioura; Taisuke Inomata; Etsuo Kunieda; Kazushige Hayakawa; Keiichi Nakagawa; Gen Kobashi; Hiroki Shirato
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-01       Impact factor: 7.038

3.  Single brain metastasis: whole-brain irradiation plus either radiosurgery or neurosurgical resection.

Authors:  Dirk Rades; Theo Veninga; Dagmar Hornung; Oliver Wittkugel; Steven E Schild; Jan Gliemroth
Journal:  Cancer       Date:  2011-07-14       Impact factor: 6.860

4.  Efficacy assessment of pemetrexed treatment of an NSCLC case with brain metastasis.

Authors:  Jing Liang; Xiaolin Liu; Beibei Yin; Hairong Liu; Junjuan Xiao; Yan Li
Journal:  Oncol Lett       Date:  2012-08-30       Impact factor: 2.967

5.  Comparison of two dose levels of stereotactic radiosurgery for 1-3 brain metastases from non-small cell lung cancer.

Authors:  Dirk Rades; Stefan Huttenlocher; Markus Dahlke; Dagmar Hornung; Oliver Blanck; Pham Van Thai; Ngo Thuy Trang; Mai Trong Khoa; Steven E Schild
Journal:  Anticancer Res       Date:  2014-12       Impact factor: 2.480

6.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Authors:  Christina A Meyers; Jennifer A Smith; Andrea Bezjak; Minesh P Mehta; James Liebmann; Tim Illidge; Ian Kunkler; Jean-Michel Caudrelier; Peter D Eisenberg; Jacobus Meerwaldt; Ross Siemers; Christian Carrie; Laurie E Gaspar; Walter Curran; See-Chun Phan; Richard A Miller; Markus F Renschler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

7.  Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1-3 brain metastases: results of a matched pair analysis.

Authors:  Dirk Rades; Jan-Dirk Kueter; Theo Veninga; Jan Gliemroth; Steven E Schild
Journal:  Eur J Cancer       Date:  2008-12-04       Impact factor: 9.162

8.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.

Authors:  Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers
Journal:  Lancet Oncol       Date:  2009-10-02       Impact factor: 41.316

9.  CyberKnife therapy of 24 multiple brain metastases from lung cancer: A case report.

Authors:  Guiqing Yang; Yishan Wang; Yuanyuan Wang; Sixiang Lin; Dongning Sun
Journal:  Oncol Lett       Date:  2013-06-07       Impact factor: 2.967

10.  Repeat stereotactic radiosurgery in the management of brain metastases from NSCLC: A case report and review of the literature.

Authors:  Giulia Marvaso; Agnese Barone; Caterina Vaccaro; Vicente Bruzzaniti; Silvia Grespi; Valerio Scotti; Cataldo Bianco
Journal:  Oncol Lett       Date:  2013-08-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.